Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano, Giuseppina Calvaruso, Rosario Di Maggio, Massimiliano Sacco, Alessandra Quota, Marcello Capra, Aldo Filosa, Domenico Giuseppe D'Ascola, Carmelo Fidone, Antonella Carollo, Lorella Pitrolo, Calogera Gerardi, Grazia Colletti, Gaetano Roccamo, Maria Antonietta Romeo, Paolo Cianciulli, Maria-Eliana Lai, Luciana Concetta Rigoli, Gianluca Forni, and Aurelio Maggio Blood Volume 124(21): December 6, 2014 ©2014 by American Society of Hematology
Estimated profiles of the mean serum ferritin in the two treatment-groups from the fitted linear mixed-effects model. Angela Vitrano et al. Blood 2014;124:1354 ©2014 by American Society of Hematology
Kaplan–Meier survival probability curves in the two treatment groups during multi-center TI clinical trial (DFP: continous line; DFO: dashed line), (p-value=0.36). Angela Vitrano et al. Blood 2014;124:1354 ©2014 by American Society of Hematology